SUSAN HILSENBECK to Survival Analysis
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Survival Analysis.
Connection Strength
0.558
-
Practical p-value adjustment for optimally selected cutpoints. Stat Med. 1996 Jan 15; 15(1):103-12.
Score: 0.097
-
Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9.
Score: 0.082
-
Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8.
Score: 0.073
-
Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.
Score: 0.045
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
Score: 0.032
-
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
Score: 0.027
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.025
-
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res. 2016 04 01; 76(7):1942-53.
Score: 0.024
-
Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012 Nov; 136(1):253-65.
Score: 0.019
-
Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
Score: 0.017
-
The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.
Score: 0.017
-
Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas. Arch Surg. 1990 Mar; 125(3):364-9.
Score: 0.016
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.
Score: 0.015
-
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
Score: 0.012
-
Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 Oct 14; 162(18):2053-7.
Score: 0.010
-
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.
Score: 0.006
-
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997 Jan; 3(1):103-9.
Score: 0.006
-
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996 Apr; 14(4):1128-35.
Score: 0.006
-
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
Score: 0.006
-
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
Score: 0.005
-
Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12.
Score: 0.005
-
Survival after first recurrence of breast cancer. The Miami experience. Cancer. 1992 Jul 01; 70(1):129-35.
Score: 0.005
-
Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.
Score: 0.005